hotspot -WSS

hotspot

author：leisure time 2025-08-22 15:48:29 - browse：7771

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Abridge raises $150m as clinical notes automation market heats up

explore

WSS

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Researchers tackle phage therapy hurdles for wider adoption

Ionis drug prevents swelling attacks due to hereditary angioedema

MD Anderson's Padmanee Sharma responds to research credit suit

Reporting on presidential health from Reagan to Trump and Biden

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

leisure time

hotspot

hotspot

Continuity nursing helped my family in our darkest PICU moments

Ionis drug prevents swelling attacks due to hereditary angioedema

Alkermes shareholders re

Researchers tackle phage therapy hurdles for wider adoption

Moonlake's readout produced a cash windfall. Risks remain

Flagship Pioneering startup Sonata Therapeutics lays off 21

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

focus

NIH documents show early flaws of $1.6 billion long Covid program

Intellia reports positive results for its CRISPR

In 'major milestone,' FDA approves first cell therapy for solid tumors

Ultragenyx gene therapy for rare liver ailment succeeds in late

Flagship Pioneering startup Sonata Therapeutics lays off 21

Opioid cravings were reduced by anti

focus

focus

explore

hotspot